Docetaxel and cisplatin as first-line chemotherapy in advanced NSCLC.

被引：0
|
作者：
Behera, D [1 ]
Aggarwal, AN [1 ]
Gupta, D [1 ]
Jindal, SK [1 ]
Sharma, SC [1 ]
机构：
[1] Postgrad Inst Med Educ & Res, Chandigarh 160012, India
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：705S / 705S
页数：1
相关论文
共 50 条
  • [31] Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer
    Minagawa, Y
    Kigawa, J
    Kanamori, Y
    Itamochi, H
    Terakawa, N
    Okada, M
    Kitada, F
    GYNECOLOGIC ONCOLOGY, 2006, 101 (03) : 495 - 498
  • [32] First line chemotherapy in advanced or metastatic NSCLC
    Rinaldi, M.
    Cauchi, C.
    Gridelli, C.
    ANNALS OF ONCOLOGY, 2006, 17 : V64 - V67
  • [33] Combined chemotherapy (CT) and erlotinib (E) as a first-line treatment of EGER-mutated (EGER M) NSCLC.
    Dudnik, Elizabeth
    Lopategui, Jean
    Chevarie-Davis, Miriam
    Natale, Ronald B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? Reply
    Mok, Tony S. K.
    Wu, Yi-Long
    LANCET ONCOLOGY, 2013, 14 (11): : E438 - E439
  • [35] LAPATINIB WITH CHEMOTHERAPY IN FIRST-LINE TREATMENT OF ADVANCED NSCLC IN NEVER SMOKERS OR SELDOM SMOKERS
    Pandey, R.
    Dey, S.
    Mukhopadhyay, A.
    LUNG CANCER, 2009, 64 : S55 - S56
  • [36] Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC
    Andric, Zoran
    Galffy, Gabriella
    Dols, Manuel Cobo
    Szima, Barna
    Stojanovic, Goran
    Petrovic, Marina
    Felip, Enriqueta
    Baz, David Vicente
    Aix, Santiago Ponce
    Juan-Vidal, Oscar
    Szalai, Zsuzsanna
    Losonczy, Gyorgy
    Blanco, Antonio Calles
    Bernabe, Reyes
    Ledo, Gema Garcia
    Hernandez, Andres Aguilar
    Duecker, Klaus
    Zhou, Dongli
    Schroeder, Andreas
    Guezel, Guelseren
    Ciardiello, Fortunato
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (02):
  • [37] Efficacy and tolerability of a weekly schedule of docetaxel-cisplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Binder, D.
    Hackenthal, M.
    Graseck, L.
    Schweisfurth, H.
    Schaeper, C.
    Kruell, M.
    Temmesfeld-Wollbrueck, B.
    Suttorp, N.
    Beinert, T.
    Hellriegel, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced NSCLC in Patients aged ≥ 70
    Shen, B.
    Pan, B.
    Wu, Y.
    Shi, L.
    Gao, J.
    Feng, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S379 - S379
  • [39] A bayesian network comparison of different agents or regimens as first-line treatment for advanced EGFR-mutated NSCLC.
    Liang, Wenhua
    He, Qihua
    Zhang, Jianrong
    Jiang, Long
    Zhou, Caicun
    He, Jianxing
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] First-line chemotherapy for NSCLC: an overview of relevant trials
    Belani, CP
    Langer, C
    LUNG CANCER, 2002, 38 : S13 - S19
12345